Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01368614
Other study ID # HRC-1006-AVAPS-AE-MS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 12, 2011
Est. completion date May 30, 2013

Study information

Verified date April 2019
Source Philips Respironics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility of using of the Average Volume Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP) and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed with Obesity Hypoventilation syndrome (OHS).

The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will yield daytime gas exchange values which are equivalent or no worse when compared to using CPAP and bilevel PSV modes of ventilation in the OHS population.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date May 30, 2013
Est. primary completion date May 30, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Age greater than or equal to 18 years of age; less than or equal to 70 years of age

- Diagnosis of Obesity Hypoventilation Syndrome via a diagnostic sleep study in the past 3 months but have not initiated therapy

- BMI greater than or equal to 30 kg/m2

- Daytime PaCO2 greater than or equal to 45 mmHg

- Apnea Hypopnea index (AHI) > 5

- Daytime pH > 7.35

- Forced Expiratory Volume at 1 second / forced vital capacity (FEV1/FVC) > 70%

Exclusion Criteria:

- Acutely ill, medically complicated or who are medically stable, or as otherwise determined by the investigator

- Respiratory alkalosis (pH > 7.45), per investigator discretion

- Emergency admissions on chronic respiratory failure

- Hospitalization for respiratory exacerbation < 6 weeks prior to screening visit

- Participants in whom PAP therapy is otherwise medically contraindicated

- Impaired upper airway function. For example, obstruction due to infections(laryngitis, epiglottis), craniofacial malformations, tumors, uvulopalatopharyngoplasty, presence of tracheostomy, or bilateral vocal cord palsy that does not allow tolerance of Non-invasive positive pressure ventilation (NPPV)

- Facial trauma, burns, surgery or anatomical abnormalities interfering with mask fit.

Study Design


Intervention

Device:
AVAPS-AE Mode of Therapy
AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
Respironics OnmiLab BiPAP S mode
Currently cleared Non-Invasive Ventilation (NIV) therapy modality
Respironics OmniLab Advanced CPAP mode
Currently cleared NIV therapy modality

Locations

Country Name City State
United States University of Chicago Chicago Illinois
United States University of Arizona School of Medicine Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Philips Respironics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) Daytime PaCO2 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks. Screening & 6 weeks
Secondary Daytime Partial Pressure of Oxygen in Arterial Blood(Pa02) Daytime Pa02 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks. Screening & 6 weeks
Secondary Apnea Hypopnea Index (AHI) The AHI is the number of apneas and hypopneas per hour of sleep. It will be evaluated during the screening sleep study and the 6 week follow up sleep study. AHI less than 5 is considered normal. For an Apnea-Hypopnea Index (or AHI) from 5 to 15 denotes mild sleep apnea. Fifteen to 30 is moderate, while a greater than 30 AHI is considered severe. Screening & 6 weeks
Secondary Epworth Sleepiness Scale Epworth Sleepiness scale is a measure of daytime sleepiness. It is a series of 8 questions answered on a scale of 0 to 3, 0 being no chance of dozing and 3 being a high chance of dozing. The range of the scale is 0 to 24. The higher the total score, the higher the chance of falling asleep. Screening & 6 weeks
Secondary Severe Respiratory Insufficiency Questionnaire (SRIQ) The SRIQ is a 49 question survey. This survey asks questions about the past week. It is answered on a scale of -2 to 2 and converted to 1 to 5, 1 is completely untrue and 5 is always true. The questionnaire is broken down into 7 sections when scoring: respiratory complaints, physical functioning, attendant systems and sleep, social relationships, anxiety, psychological well-being and social functioning. Once each scale score is calculated. The average score can be calculated by taking the mean of the subscales. This process of transformation produces a score between 0 and 100 with higher values indicating a better health-related quality of life according to content of the scale. Screening & 6 weeks
Secondary Ventilator Adherence - Average Hours The average number of hours ventilator was used per each day used. 6 weeks
Secondary Ventilator Adherence - Days Used Average number of days used per week 6 weeks
Secondary Actigraphy Actigraphy is a method of measuring activity and sleep which is achieved by wearing a small watch-like device for an extended period of time. The data is intended to provide an objective measure of physical activity and sleep / week patterns during pre / post sleep studies and throughout the 6 weeks of home use. Screening & 6 weeks
Secondary Room Air Sp02 Assessment Via Pulse Oximetry Oxygen saturation measurements as determined by pulse oximetry Screening & 6 weeks
Secondary Nocturnal Transcutaneous Capnography (TcC02) Nocturnal Transcutaneous Capnography is a non-invasive monitoring tool to measure ventilation over the night. Screening & 6 weeks
Secondary Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Duration Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Total sleep time in each stage provides the average amount of time a participant was in that stage of sleep. This includes Stage 1, Stage 2, Stage 3/4, and Rapid Eye Movement (REM) sleep. Screening & 6 weeks
Secondary Duration and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Sleep Efficiency Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Sleep efficiency is measured by the total time a participant is spent asleep. Screening & 6 weeks
Secondary Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Arousal and Awakening Indices The arousal index is measured by the average number of arousals or awakenings a participant has over an hour of sleep. Screening & 6 weeks
Secondary Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Nocturnal O2 Saturation Measurement of overnight oxygen saturation as measured by percentage of oxygen saturation (SpO2) Screening & 6 weeks
Secondary Reaction Time (Psychomotor Vigilance Test-PVT) To measure trends of vigilance between the baseline screening assessment and the 6 week follow up visit comparing the three Arms/Groups. This measured how quickly participants reacted to visual stimulus. Reaction time is the latency at which the participant reacts to a visual stimulus > 100 ms. Screening & 6 weeks
Secondary Number of Participants With Need for Continued Oxygen Supplementation Some users enrolled into the study required supplemental oxygen at different times during the day: at rest, during exertion and at night. The need for supplemental oxygen was compared at baseline and at 6 weeks. Screening & 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT01903135 - Prevalence of Obesity Hypoventilation Syndrome N/A
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Withdrawn NCT03861468 - Medico-economics and QoL of Obese Patients Followed by Medical Analysis Laboratories (BIOSAOS ) N/A
Terminated NCT01964339 - Obesity Hypoventilation Syndrome Prevalence Study
Completed NCT04108819 - Ketogenic Diet for Obesity Hypoventilation Syndrome N/A
Completed NCT02934581 - Prevalence Rate, and Clinical Characteristics of Obesity Hypoventilation Syndrome Via Screening Patients Admitted to Medical Intensive Care Units
Terminated NCT03353064 - Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure N/A
Completed NCT03085537 - Effectiveness Monitoring of Home Non-invasive Mechanical Ventilation by Digital Diagnosis Platform
Recruiting NCT02980770 - Postoperative Complications in Patients With Obesity Hypoventilation Syndrome N/A
Completed NCT01499485 - Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation. Phase 3
Completed NCT01483716 - A Trial of Rehabilitation in Obesity Hypoventilation Syndrome (OHS) N/A
Completed NCT03506906 - The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation N/A
Terminated NCT02317042 - Juno Perth Clinical Trial N/A
Withdrawn NCT01104610 - Target Volume Mode Controlled Ventilator in Obesity Hypoventilation Syndrome N/A
Completed NCT01405976 - Alternative of Treatment in Obesity Hypoventilation Syndrome N/A
Recruiting NCT03854058 - Respiratory Muscle Strength in Patients With Obesity Hypoventilation Syndrome (OHS) or With a Precursor of the Disease
Not yet recruiting NCT05190458 - Evaluation of High Velocity Nasal Insufflation in Management of Respiratory Failure in Patients With Overlap Syndrome N/A
Recruiting NCT04100616 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity
Completed NCT02342899 - Cost Effectiveness of Outpatient Set-up of Automated NIV in Obese Patients With Chronic Respiratory Failure Phase 3
Completed NCT01757444 - Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS N/A